Company Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 487 |
| CEO | Barry Greene |
Contact Details
Address: 215 First Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 299 8380 |
| Website | sagerx.com |
Stock Details
| Ticker Symbol | SAGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597553 |
| CUSIP Number | 78667J108 |
| ISIN Number | US78667J1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Barry E. Greene | President, Chief Executive Officer and Director |
| Christopher Benecchi | Chief Operating Officer |
| Dr. Laura Gault M.D., Ph.D. | Chief Medical Officer |
| Mike Quirk Ph.D. | Chief Scientific Officer |
| Ashley Kaplowitz | Director of Investor Relations |
| Gregory Shiferman | Senior Vice President and General Counsel |
| Pamela Herbster | Vice President and Head of People |
| Dr. Helen Colquhoun | Senior Vice President of Drug Safety and Pharmacovigilance |
| Vanessa Procter | Senior Vice President of Corporate Affairs |
| Dr. Aaron Koenig M.D. | Medical Director of Early Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 144 | Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | 8-K | Current Report |